Vitamin D receptor gene polymorphisms and cognitive decline in Parkinson's disease

- Fokl, a functional VDR polymorphism, is associated with cognitive decline in Parkinson's disease
- Each additional copy of the FokI A allele was associated with a 0.115 decrease in total MMSE score per year of follow-up
- This was comparable in magnitude to that for disease duration in years prior to first interview and years of education

We and others have suggested that vitamin D receptor gene (VDR) polymorphisms influence susceptibility for Parkinson's disease (PD), Alzheimer's disease (AD), mild cognitive impairment (MCI) or overall cognitive functioning. Here we examine VDR polymorphisms and cognitive decline in patients with PD. Non-Hispanic Caucasian PD patients (n = 190) in the Parkinson Environment Gene (PEG) study were successfully genotyped for seven VDR polymorphisms. Cognitive function was assessed with the Mini-Mental State Exam (MMSE) at baseline and at a maximum of three follow-up exams. Using repeated-measures regression we assessed associations between VDR SNP genotypes and change in MMSE longitudinally. PD cases were on average 67.4 years old at diagnosis and were followed for an average of 7.1 years into disease. Each additional copy of the FokI A allele was associated with a 0.115 decrease in the total MMSE score per year of follow-up (β = − 0.115, SE(β) = 0.05, p = 0.03) after adjusting for age, sex, education and PD duration. The effect on MMSE by the FokI A allele was comparable in absolute magnitude to the effect for disease duration in years prior to first interview (β = − 0.129 per year, SE(β) = 0.08, p = 0.13), and years of education (β = 0.118 per year, SE(β) = 0.03, p < 0.001). When LD/LED use and PD subtype were added to the model, the effect of the FokI A allele on total MMSE score was magnified (β = − 0.141, SE(β) = 0.05, p = 0.005). Results point to Fokl, a functional VDR polymorphism, as being associated with cognitive decline in PD. Future studies examining the contributions of the vitamin D metabolic pathway to cognitive dysfunction in PD are needed.